Viewing Study NCT05873205


Ignite Creation Date: 2025-12-25 @ 3:21 AM
Ignite Modification Date: 2026-03-03 @ 6:15 AM
Study NCT ID: NCT05873205
Status: RECRUITING
Last Update Posted: 2025-07-29
First Post: 2023-05-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module